文献速递白血病

接受低强度治疗的急性髓系白血病患者的可测量残留病监测:ELN-DAVID专家小组路线图

Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
PubMed 文献 · Am J Hematol · 2023-09-06

欧洲白血病网(ELN)-DAVID急性髓系白血病可测量残留病(MRD)工作组专家审阅现有数据,提出低强度方案治疗患者MRD检测的框架,并通过德尔菲投票优化共识。报告指出统一MRD评估标准对优化检测和改善治疗结局具有临床相关性。

要点

  • 低强度方案治疗AML患者中MRD检测的价值尚不明确。
  • 专家小组提出未来试验和临床实践中MRD检测的框架路线图。
  • 建立低强度方案MRD评估的统一标准具有临床相关性。

核心结论

  • 建立用于AML低强度方案治疗患者的MRD评估统一标准具有临床相关性,对优化检测并最终改善这些患者的治疗结局重要。

研究设计与样本

  • 欧洲白血病网(ELN)-DAVID AML MRD工作组专家审阅所有可用数据,提出未来试验和临床实践中MRD检测的框架,并通过德尔菲投票优化共识。

主要发现

  • 过去几年AML管理发生显著变化,尤其是被认为不适合强化化疗的患者。
  • 强化化疗患者中MRD检测已常规开展以细化预后并可能指导治疗决策,但其在低强度方案背景下的价值尚不明确。
  • 低强度方案日益普及且可伴随较高缓解率,明确MRD评估作用及适当时机和检测方法的需求增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the availability of effective targeted agents, significant changes have occurred in the management of patients with acute myeloid leukemia (AML) over the past several years, particularly for those considered unfit for intensive chemotherapy. While testing for measurable residual disease (MRD) is now routinely performed in patients treated with intensive chemotherapy to refine prognosis and, possibly, inform treatment decision-making, its value in the context of lower-intensity regimens is unclear. As such regimens have gained in popularity and can be associated with higher response rates, the need to better define the role of MRD assessment and the appropriate time points and assays used for this purpose has increased. This report outlines a roadmap for MRD testing in patients with AML treated with lower-intensity regimens. Experts from the European LeukemiaNet (ELN)-DAVID AML MRD working group reviewed all available data to propose a framework for MRD testing in future trials and clinical practice. A Delphi poll served to optimize consensus. Establishment of uniform standards for MRD assessments in lower-intensity regimens used in treating patients with AML is clinically relevant and important for optimizing testing and, ultimately, improving treatment outcomes of these patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ravandi F, Cloos J, Buccisano F, et al. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel. Am J Hematol. 2023. PMID: 37671649. doi:10.1002/ajh.27087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。